314 related articles for article (PubMed ID: 32427480)
1. Biopharmaceutic
Arora S; Pansari A; Kilford P; Jamei M; Gardner I; Turner DB
Mol Pharm; 2020 Jul; 17(7):2329-2344. PubMed ID: 32427480
[TBL] [Abstract][Full Text] [Related]
2. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
[TBL] [Abstract][Full Text] [Related]
3. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story.
Emami Riedmaier A; Lindley DJ; Hall JA; Castleberry S; Slade RT; Stuart P; Carr RA; Borchardt TB; Bow DAJ; Nijsen M
J Pharm Sci; 2018 Jan; 107(1):495-502. PubMed ID: 28993217
[TBL] [Abstract][Full Text] [Related]
5. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
6. Biorelevant Two-Stage In Vitro Testing for rDCS Classification and in PBPK Modeling-Case Example Ritonavir.
Fiolka T; Van Den Abeele J; Augustijns P; Arora S; Dressman J
J Pharm Sci; 2020 Aug; 109(8):2512-2526. PubMed ID: 32387425
[TBL] [Abstract][Full Text] [Related]
7. Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base Ritonavir with Equivalent In Vitro and In Vivo Performance to Norvir Tablet.
Ellenberger DJ; Miller DA; Kucera SU; Williams RO
AAPS PharmSciTech; 2018 Jul; 19(5):1985-1997. PubMed ID: 29869311
[TBL] [Abstract][Full Text] [Related]
8. On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state.
O'Dwyer PJ; Box KJ; Imanidis G; Vertzoni M; Reppas C
Eur J Pharm Sci; 2022 Jan; 168():106034. PubMed ID: 34628003
[TBL] [Abstract][Full Text] [Related]
9. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
Arora S; Pansari A; Kilford PJ; Jamei M; Turner DB; Gardner I
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):483-495. PubMed ID: 35486324
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions.
Koenigsknecht MJ; Baker JR; Wen B; Frances A; Zhang H; Yu A; Zhao T; Tsume Y; Pai MP; Bleske BE; Zhang X; Lionberger R; Lee A; Amidon GL; Hasler WL; Sun D
Mol Pharm; 2017 Dec; 14(12):4295-4304. PubMed ID: 28937221
[TBL] [Abstract][Full Text] [Related]
11. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.
Shono Y; Jantratid E; Dressman JB
Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341
[TBL] [Abstract][Full Text] [Related]
12. Biopharmaceutic IVIVE-Mechanistic Modeling of Single- and Two-Phase In Vitro Experiments to Obtain Drug-Specific Parameters for Incorporation Into PBPK Models.
Pathak SM; Schaefer KJ; Jamei M; Turner DB
J Pharm Sci; 2019 Apr; 108(4):1604-1618. PubMed ID: 30476508
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal and Systemic Disposition of Diclofenac under Fasted and Fed State Conditions Supporting the Evaluation of in Vitro Predictive Tools.
Van Den Abeele J; Schilderink R; Schneider F; Mols R; Minekus M; Weitschies W; Brouwers J; Tack J; Augustijns P
Mol Pharm; 2017 Dec; 14(12):4220-4232. PubMed ID: 28621952
[TBL] [Abstract][Full Text] [Related]
14. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.
Patel N; Polak S; Jamei M; Rostami-Hodjegan A; Turner DB
Eur J Pharm Sci; 2014 Jun; 57():240-9. PubMed ID: 24060671
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic Modeling of In Vitro Biopharmaceutic Data for a Weak Acid Drug: A Pathway Towards Deriving Fundamental Parameters for Physiologically Based Biopharmaceutic Modeling.
Kowthavarapu VK; Charbe NB; Gupta C; Iakovleva T; Stillhart C; Parrott NJ; Schmidt S; Cristofoletti R
AAPS J; 2024 Apr; 26(3):44. PubMed ID: 38575716
[TBL] [Abstract][Full Text] [Related]
16. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
[TBL] [Abstract][Full Text] [Related]
17. Physiologically-Based Pharmacokinetic Modeling of PAXLOVID™ with First-Order Absorption Kinetics.
Sagawa K; Lin J; Jaini R; Di L
Pharm Res; 2023 Aug; 40(8):1927-1938. PubMed ID: 37231296
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavir.
Miller DA; Keen JM; Brough C; Ellenberger DJ; Cisneros M; Williams RO; McGinity JW
J Pharm Pharmacol; 2016 May; 68(5):678-91. PubMed ID: 26454138
[TBL] [Abstract][Full Text] [Related]
19. In-vitro-in-silico investigation of the negative food effect of zolpidem when administered as immediate-release tablets.
Paraiso RLM; Watanabe A; Andreas CJ; Turner D; Zane P; Dressman J
J Pharm Pharmacol; 2019 Nov; 71(11):1663-1676. PubMed ID: 31566757
[TBL] [Abstract][Full Text] [Related]
20. The effect of reduced gastric acid secretion on the gastrointestinal disposition of a ritonavir amorphous solid dispersion in fasted healthy volunteers: an in vivo - in vitro investigation.
Van Den Abeele J; Kostantini C; Barker R; Kourentas A; Mann JC; Vertzoni M; Beato S; Reppas C; Tack J; Augustijns P
Eur J Pharm Sci; 2020 Aug; 151():105377. PubMed ID: 32461076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
